Baker Bros. Opened Positions In These 5 Healthcare Stocks

Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

– Shares Owned by Baker Bros. Advisors (as of June 30): 217,328

– Value of Baker Bros. Advisors’ holding (as of June 30): $5.43 million

Julian and Felix Baker’s Baker Bros. Advisors also initiated a stake in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) and reported holding 217,328 shares whose value stood at $5.43 million. The company reported a second-quarter net loss of $0.79 per share, which missed the estimates by $0.04 per share, while revenue stood at $0.01 million for the second quarter (it did not have any revenue in the second quarter of 2015). The company continues to make significant progress on ALD403 and is advancing towards BLA submission. ALD403 is engaged in untried monoclonal antibody treatment with a focus on calcitonin gene-related peptide which is also known as CGRP and is meant for prevention of migraine. CGRP is a critical because of protein content though in small is mixed up between the transmission and increased sensitivity towards pain experienced by patients affected by migraine. Migraine is regarded as big cause of disability affecting individuals aged between 20 years to 50 years which is considered to be the most productive period. Among the funds we track, 23 investors reported stakes in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) worth $253.17 million in aggregate as of the end of June.

Minerva Neurosciences Inc (NASDAQ:NERV)

– Shares Owned by Baker Bros. Advisors (as of June 30): 508,405

– Value of Baker Bros. Advisors’ holding (as of June 30): $5.19 million

The Julian and Felix Baker’s Baker Bros. Advisors added 508,405 shares of Minerva Neurosciences Inc (NASDAQ:NERV) worth $5.19 million during second quarter. Following a jump in May, Minerva’s stock is up by more than 100% year-to-date. On May 26, the company reported that its Phase 2b clinical trial that assessed its lead product candidate, MIN-101, met its primary endpoint in improving negative symptoms in patients with schizophrenia. For the second quarter, Minerva Neurosciences Inc (NASDAQ:NERV) reported net loss of $0.18 per share against expected net loss of $0.30. The company also had cash and cash equivalent balance of $97.1 million compared to $32.2 million on December’15 and did not generate any revenue. A total of 16 funds followed by Insider Monkey have long positions in Minerva Neurosciences Inc (NASDAQ:NERV) with a total value of $72.05 million as of the end of the second quarter.

Syros Pharmaceuticals Inc (NASDAQ:SYRS)

– Shares Owned by Baker Bros. Advisors (as of June 30): 204,465

– Value of Baker Bros. Advisors’ holding (as of June 30): $3.71 million

The fifth new stock added by Julian and Felix Baker’s Baker Bros. Advisors is Syros Pharmaceuticals Inc (NASDAQ:SYRS). The fund bought 204,465 shares worth $3.71 million between May and June. Recently, the company announced that its founders have employed a novel chemistry approach which validates CDK12 and CDK13 which plays an important role in controlling gene expression. Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play an significant role in gene transcription. Absence of CDK12 and CDK13 is one of the key hurdle which has impacted in identifying the cause of various types of cancer. “A key focus of our proprietary gene control platform is understanding and drugging transcriptional targets, including transcriptional kinases. By modulating these targets with small molecules, we aim to control the expression of the critical set of genes driving the disease with a single drug,” said Eric Olson, Ph.D., Syros’ Chief Scientific Officer. Syros is another company that went public earlier this year and since its IPO at the end of June its stock has lost 27%. Six investors from our database owned shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) at the end of the second quarter, having amassed $75.47 million worth of stock.

Disclosure: None